Consultation: Draft guidance on decentralized clinical trials

Current status: Open

Opened on December 23, 2025, and will close to new input on February 21, 2026.

Health Canada has drafted a guidance document on decentralized clinical trials. The draft guidance outlines regulatory considerations and practical strategies for conducting clinical trials with decentralized elements in Canada. These considerations are set out in Part C, Division 5 of the Food and Drug Regulations and supported by the International Council for Harmonization Guideline for Good Clinical Practice (ICH E6).

We’re also modernizing how clinical trials are regulated to better accommodate new trial types and designs.

Join in: how to participate

Send us an email

Send an email to bpsip-bpspiconsultation@hc-sc.gc.ca with your ideas or comments to make yourself heard.

Participate by mail

Send a letter with your ideas and input to the address provided below.

Who is the focus of this consultation

We will engage with interested parties, including:

Key points about the draft guidance

The draft guidance explains the current regulatory requirements and other considerations for decentralized clinical trials. In decentralized trials, some or all trial-related activities take place at locations other than traditional clinical trial centres with the help of digital health technologies and virtual methods.

Decentralized elements can:

The draft guidance is being published for consultation. We will develop the final version of this guidance based on public feedback.

Contact us

Bureau of Policy, Science and International Programs
Pharmaceutical Drugs Directorate
Health Products and Food Branch
Health Canada
1600 Scott St.

Address Locator: 3106B
Ottawa ON  K1A 0K9
Email: bpsip-bpspiconsultation@hc-sc.gc.ca

Page details

From:

2025-12-23